Table 1. Summary of articles about LGL lymphocytosis during daatinib therapy.
| Reference | No. of patients | Median age (years) | Dasatinib dose (mg/d) | Rate of LGL lymphocytosis | Lymphocyte counts (109/L) | Median interval from starting dasatinib to LGL | Median number of LGL (109/L) |
|---|---|---|---|---|---|---|---|
| Mustjoki et al.15 | 30 | 54 (25–76) | 140 | 73% (22) | 4–20 | 3 mo (range 1–15 mo) | NR |
| Kreutzman et al.16 | 20 | 51 (29–78) | NR | 50% (10) | NR | NR | NR (range 4–20) |
| Nagata et al.17 | 20 | 50 (29–81) | 100–180 | 45% (9) | NR | 1 mo (range 1–8 mo) | 6.5 (range 2.9–17.4) |
| Kim et al.18 | 18 | NR | 140 | 44% (8) | 4.6–8.8 | 4 mo (range 1.5–15 mo) | NR (range 2.2–5.6) |
| Tanaka et al.19 | 25 | 64 (20–84) | 50–140 | 60% (12) | NR | 11 wk (range 6–44 wk) | 3.0 (range 1.6–6.0) |
| Valent et al.20 | 15 | NR | 100–140 | 27% (4) | 5.0–6.9 | NR | NR (range 2.3–4.83) |
| Lee et al.21,* | 50 | 49 | 100–140 | 46% (23) | 3.7–7.9 | 4 mo (range 1–13 mo) | NR |
| Powers et al.22 | 16 | 56 (48–65) | NR | 31% (5) | NR | NR | 1.6 (range 0.6–2.7) |
Note: *In this study, the development of lymphocytosis could not be directly interpreted as an expansion of large granular lymphocytes because a PB smear was not available; NR, not reported.